Publication of Clinical Study Results
Since 2020, Gilead discloses clinical study results of newly authorized treatments in Switzerland by Swissmedic according to the requirements laid out in Art. 71-73 TPO (Ordinance on Therapeutic Products).
Therapies are listed in alphabetical order.
| Product | Active Substance | Authorization Number | Date of Authorization |
|---|---|---|---|
| Hepcludex® | Bulevirtid | 68338 | 05.02.2024 |
| Sunlenca® | Lenacapavir | 68385 / 68386 | 07.07.2023 |
| Tecartus® | Autologous anti-CD19-transducedCD3+ cells | 67884 | 25.08.2021 |
| Trodelvy® | Sacituzumab govitecan | 68179 | 09.09.2021 |
| Veklury® | Remdesivir | 68026 / 68043 | 25.11.2020 |